COVID-19 and the brain: Meyer and colleagues provide a systematic review of current literature on the applications and findings of molecular imaging techniques in elucidating the effects of COVID-19 on the human brain.. . . . . ***Page 971***

Alzheimer disease standards of care: Teipel and colleagues summarize standards of diagnosis (including advances in molecular imaging), treatment, care, and prevention of Alzheimer disease. . . . . ***Page 981***

Radiotracers in cardiovascular imaging: Stendahl and colleagues highlight current and promising radiotracers for imaging cardiovascular inflammation, thrombosis, fibrosis, calcification, and amyloidosis, with a focus on addressing unmet clinical needs. . . . . ***Page 986***

Women authors in nuclear medicine journals: Lasnon and colleagues evaluate recent trends in the gender distribution of first and last authorship of articles published in nuclear medicine journals.. . . . . ***Page 995***

PET and DLBCL response prediction: Burggraaff and colleagues explore the value added by baseline metabolic tumor volume and interim PET to conventional prognostic indices for 2-y progression-free survival in diffuse large B-cell lymphoma and investigate optimal interim PET response criteria. . . . . ***Page 1001***

^{18}F-FDG PET molecular signatures in MM: Alberge and colleagues identify gene expression patterns associated with prognostic ^{18}F-FDG PET biomarkers in newly diagnosed multiple myeloma patients included in the prospective multicenter CASSIOPET study. . . . . ***Page 1008***

PET tumor burden and NET prognosis: Thuillier and colleagues investigate the prognostic value of somatostatin receptor tumor burden on ^{68}Ga-DOTATOC PET/CT in patients with well-differentiated neuroendocrine tumors. . . . . ***Page 1014***

FAPi PET versus FAP IHC: Mona and colleagues report on the spectrum of fibroblast-activation protein expression across various cancers by immunohistochemistry and explore whether ^{68}Ga–FAP inhibitor–46 PET biodistribution accurately reflects FAP expression from resected cancer and noncancer specimens.. . . . . ***Page 1021***

^{68}Ga-DOTATATE PET FTV in NETS: Reddy and colleagues compare multiple PET functional tumor volume computational approaches and morphologic volume measurements to identify a candidate for incorporation into ^{68}Ga-DOTATATE PET FTV studies to more accurately assess neuroendocrine tumor burden. . . . . ***Page 1027***

GPC3-targeted ^{227}Th therapy for HCC: Labadie and colleagues describe the development and in vivo efficacy of a ^{227}Th-labeled glypican-3–targeting antibody conjugate for treatment of hepatocellular carcinoma in an orthotopic murine model. . . . . ***Page 1033***

Enhancing ^{223}Ra efficacy: Paindelli and colleagues test the effect of a cotargeting strategy combining ^{223}Ra and anti–β1 integrin antibody treatment in PC3 and C4-2B prostate cancer cell models expressing high and low β1 integrin levels. . . . . ***Page 1039***

Pretargeting and trastuzumab combination: Oroujeni and colleagues test in mice a combination of Affibody-based peptide nucleic acid–mediated pretargeted radionuclide therapy and trastuzumab treatment of HER2-expressing xenografts to extend survival.. . . . . ***Page 1046***

^{18}F-flortaucipir PET in PSP: Malpetti and colleagues use a data-driven approach to determine whether postmortem pathologic staging in progressive supranuclear palsy can be reproduced in vivo with ^{18}F-flortaucipir PET. . . . . ***Page 1052***

Cognition and ^{18}F-FDG PET in long COVID: Dressing and colleagues assess cognitive profiles and the potential of regional cerebral glucose metabolism as a biomarker of neuronal function in outpatients with long-term neurocognitive symptoms after COVID-19. . . . . ***Page 1058***

^{11}C-PiB PET in AL cardiac amyloidosis: Choi and colleagues determine the independent prognostic value of ^{11}C-Pittsburgh compound B PET/CT in staging and risk assessment in patients with amyloid light-chain cardiac amyloidosis. . . . . ***Page 1064***

V/P scintigraphy in COVID-19: Le Roux and colleagues evaluate the role of ventilation imaging when lung scintigraphy is performed because of suspected pulmonary embolism in COVID-19 patients and describe associated practices and imaging findings in this population. . . . . ***Page 1070***

^{90}Y radioembolization lung dose and toxicity: Stella and colleagues characterize the relationship between lung dose and eventual occurrence of radiation pneumonitis in patients after ^{90}Y-microsphere liver radioembolization. . . . . ***Page 1075***

^{18}F-FCH PET/CT in PHPT: Boudousq and colleagues compare contrast-enhanced ^{18}F-fluorocholine PET/CT, cervical ultrasonography, and conventional scintigraphic imaging, combined and individually, for preoperative localization of hyperfunctional parathyroids in patients with primary hyperparathyroidism. . . . . ***Page 1081***

PET/CT cervical cancer radiomics: Yusufaly and colleagues develop and validate a model incorporating nontumor PET/CT radiomics, including whole-body features, to predict treatment outcomes in patients with previously untreated locoregionally advanced cervical cancer. . . . . ***Page 1087***

^{124}I-Omburtamab in DSRCT: Grkovski and colleagues use serial PET/CT to assess the pharmacokinetics, biodistribution, and radiation dosimetry of ^{124}I-omburtamab administered intraperitoneally in patients with desmoplastic small round cell tumors. . . . . ***Page 1094***

^{90}Y total-body PET TARE dosimetry: Costa and colleagues assess the suitability of the total-body PET/CT uEXPLORER for imaging ^{90}Y-microsphere transarterial radioembolization and investigate possible improvements in associated PET-based dosimetry. . . . . ***Page 1101***

Toward patient-specific kidney phantoms: Theisen and colleagues present a methodology for designing single-compartment kidney phantoms for SPECT/CT that mimic inhomogeneous spatial activity distributions, with potential for reducing uncertainties in planning and monitoring individualized radionuclide therapies. . . . . ***Page 1108***

PET drug workshop: Bunning and participants detail the proceedings of a workshop on inspections management and regulatory considerations for radiopharmaceuticals held in 2020 at the U.S. Food and Drug Administration. . . . . ***Page 1117***